Schering-Plough announced that the device used to deliver NASONEX(R) (mometasone furoate monohydrate) nasal spray for the treatment of nasal allergy symptoms has received the Arthritis Foundation’s Ease-of-Use Commendation. The commendation recognizes products that provide accessibility or ease-of-use for people with arthritis as determined by an independent lab experienced in the design and evaluation of products and individuals with various forms of the chronic illness.
“Products that receive the Ease-of-Use Commendation have been shown to make everyday tasks, like administering a medication, easy and comfortable for people with arthritis,” said Mary Norman, Arthritis Foundation group vice president of strategic marketing alliances.
The Arthritis Foundation created the Ease-of-Use Commendation Program to encourage manufacturers to design user-friendly products and packaging that could be recommended to the nearly 46 million Americans who are affected by some form of arthritis.(1.) The NASONEX delivery device is the first nasal allergy spray to have the Ease-of-Use Commendation from the Foundation.
An estimated 37 million Americans suffer from the symptoms of seasonal and perennial allergies.(2.) A nasal-inhaled steroid, such as NASONEX, is a recommended first-line therapy for all nasal symptoms of allergic rhinitis.(3.) NASONEX is the only once-daily prescription intranasal corticosteroid approved to help prevent seasonal nasal allergy symptoms in adults and children 12 years of age and older when NASONEX is started 2 to 4 weeks prior to allergy season. NASONEX is also the only intranasal corticosteroid approved to treat nasal allergy symptoms, including nasal congestion, in patients as young as 2 years of age.